Amundi boosted its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 175.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,978 shares of the company's stock after acquiring an additional 27,989 shares during the quarter. Amundi's holdings in Myriad Genetics were worth $650,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of MYGN. Point72 Hong Kong Ltd purchased a new position in Myriad Genetics during the 3rd quarter valued at $32,000. KBC Group NV raised its position in Myriad Genetics by 132.8% during the 4th quarter. KBC Group NV now owns 5,845 shares of the company's stock valued at $80,000 after purchasing an additional 3,334 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. raised its position in Myriad Genetics by 43.8% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company's stock valued at $132,000 after purchasing an additional 1,471 shares in the last quarter. Meeder Asset Management Inc. raised its position in Myriad Genetics by 588.4% during the 3rd quarter. Meeder Asset Management Inc. now owns 4,922 shares of the company's stock valued at $135,000 after purchasing an additional 4,207 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in Myriad Genetics during the 3rd quarter valued at $153,000. Hedge funds and other institutional investors own 99.02% of the company's stock.
Myriad Genetics Stock Performance
Myriad Genetics stock traded up $0.10 during trading hours on Friday, hitting $10.01. 1,905,019 shares of the stock traded hands, compared to its average volume of 853,059. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. The firm's 50 day moving average price is $12.14 and its 200-day moving average price is $17.11. The stock has a market capitalization of $914.00 million, a price-to-earnings ratio of -7.70 and a beta of 1.79. Myriad Genetics, Inc. has a 1 year low of $9.36 and a 1 year high of $29.30.
Myriad Genetics (NASDAQ:MYGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.12). The firm had revenue of $210.60 million for the quarter, compared to analysts' expectations of $210.35 million. Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. During the same quarter in the previous year, the firm posted ($0.12) EPS. As a group, equities analysts expect that Myriad Genetics, Inc. will post -0.3 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on the company. Bank of America decreased their target price on Myriad Genetics from $13.00 to $11.00 and set an "underperform" rating for the company in a research report on Monday, March 3rd. Piper Sandler raised Myriad Genetics from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $11.50 to $12.50 in a research report on Wednesday, March 12th. Leerink Partnrs lowered Myriad Genetics from a "strong-buy" rating to a "hold" rating in a research report on Monday, December 9th. UBS Group reduced their price target on Myriad Genetics from $18.00 to $16.00 and set a "neutral" rating for the company in a research report on Tuesday, February 25th. Finally, The Goldman Sachs Group reduced their price target on Myriad Genetics from $29.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Myriad Genetics currently has an average rating of "Hold" and a consensus price target of $21.89.
Read Our Latest Analysis on Myriad Genetics
Myriad Genetics Profile
(
Free Report)
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Featured Stories
Before you consider Myriad Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myriad Genetics wasn't on the list.
While Myriad Genetics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
